Phillip Stubblefield – författare

Many diseases earlier considered to be incurable are now being treated with modern innovations involving fetal tissue transplants and stem cells derived from fetal tissues. Fetal tissues are the richest source of fetal stem cells as well as other varying states of differentiated cells and support or stromal cells. The activity of such stem cells is at their peak provided they are given the correct niche. Stem cells, as we know, are immortal cells with the capacity to regenerate into any kind of differentiated cell as per niche-guidance. As such, fetal tissues have the potential capacity to mend, regenerate and repair damaged cells or tissues in adults, when directly transplanted to the site of injury, or even when transplanted in some other site, because it may have a homing capacity to migrate to the site of the specific injured organ. This is a new area of translational research and needs to be highlighted because of its immense potential. This book will bring together the new work of prominent medical scientists and clinicians who are conducting pioneering research in human fetal tissue transplantation. This will include direct transplant of healthy fetal tissue into mature patients as well as in hosts with genetic diseases. Transplant techniques, donor-host interaction, cell and tissue storage, ethical and legal issues, are some of the many matters which the book will deal with.

The proposed book is a holistic review of the clinical use of placental substances, amniotic fluid, the umbilical cord and its contents. It is intended to be a unique presentation of the current advances as well as also discussing the future applications of these substances.Attention is yet to be focused on the widespread clinical use of pregnancy-related biological substances. The aim for this book is to inform clinicians of the use of such materials and increase awareness of their therapeutic benefits. As such, this reference resource will be of great value to hematologists, rheumatologists, cardiologists, transplant technologists and all involved in regenerative medicine.

Many diseases earlier considered to be incurable are now being treated with modern innovations involving fetal tissue transplants and stem cells derived from fetal tissues. Fetal tissues are the richest source of fetal stem cells as well as other varying states of differentiated cells and support or stromal cells.

Cord blood is a significant source of hematopoietic stem and progenitor cells for the treatment of blood and genetic disorders. Cord blood is also an alternative to embryos as a source of tissue for regenerative medicine. Cells from cord blood have been shown to transdifferentiate into nonhematopoietic cells, including those of the brain, heart, liver, pancreas, bone, and cartilage, in tissue culture and in animal systems. Recently it has been demonstrated that both cardiac and glial cell differentiation of cord blood donor cells occurred in recipients of unrelated donor cord blood transplantation as part of a treatment regime for Krabbe disease and Sanfilippo syndrome. These observations raise the possibility that cord blood may serve as a source of cells to facilitate tissue repair and regeneration in the future. CD34 stem cell-rich umbilical cord whole blood transfusion has the potential to have an immediate benefit of better tissue oxygenation with an additional delayed benefit of possible engraftment of umbilical cord stem cells.

The proposed book is a holistic review of the clinical use of placental substances, amniotic fluid, the umbilical cord and its contents. It is intended to be a unique presentation of the current advances as well as also discussing the future applications of these substances.Attention is yet to be focused on the widespread clinical use of pregnancy-related biological substances. The aim for this book is to inform clinicians of the use of such materials and increase awareness of their therapeutic benefits. As such, this reference resource will be of great value to hematologists, rheumatologists, cardiologists, transplant technologists and all involved in regenerative medicine.